Treatment of PTEN-Null Breast Cancer by a Synthetic Lethal Approach Involving PARP1 Gene Silencing
Journal of Pharmaceutical Sciences · 2023
DOI: 10.1016/j.xphs.2023.02.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2023. Verfasst von Tomohiro Asai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan. Electro…. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, JSPS.
Abstract (Originalsprache)
The loss of the phosphatase and tensin homolog (PTEN) deleted from chromosome 10 is frequently observed in a variety of human cancers and appears to be an ideal target in synthetic lethality-based treatment. In this study, the synthetic lethal interaction between PTEN loss and the gene silencing of poly [ADP-ribose] polymerase 1 (PARP1) was examined in human triple-negative breast cancer cells (PTEN-null MDA-MB-468 and PTEN-positive MDA-MB-231 cells). Polycation liposomes previously developed by us were employed to deliver the small interfering ribonucleic acid (siRNA) targeted toward PARP1 (siPARP1) into the cancer cells. The silencing of the PARP1 gene exerted a cytocidal effect on the MDA-MB-468 cells but had no effect on the MDA-MB-231 cells and the human umbilical vein endothelial cells employed as normal cells. The simultaneous knockdown of PARP1 and PTEN in the MDA-MB-231 cells resulted in the significant inhibition of cell growth. The data suggest that the effects of the PARP1 knockdown on the cells were dependent on the PTEN status. A significant increase in the DNA breaks and the extent of apoptosis, possibly due to the failure of DNA repair, was observed upon PARP1 knockdown in the MDA-MB-468 cells compared with the case in the MDA-MB-231 cells. Our findings suggest that the synthetic lethal approach via PARP1 gene silencing holds promise for the treatment of patients with PTEN-null breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan. Electronic address: asai@u-shizuoka-ken.ac.jp.
- Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
- Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Japan Society for the Promotion of Science (JSPS), 8 Ichibancho, Chiyoda-ku,…
- Department of Life and Materials Engineering, Nagoya Institute of Technology, Gokiso-cho, Showa-ku, Nagoya, Aichi, 466-8555 Japan.
- Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan; Faculty of Pharma-Science, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo…
Förderung
- Japan Society for the Promotion of Science
- JSPS
Zitieren
APA
Asai, T., Yokota, M., Isomura, H., Koide, H., Sakurai, N., Okamoto, A., Ando, H., Dewa, T., & Oku, N. (2023). Treatment of PTEN-Null Breast Cancer by a Synthetic Lethal Approach Involving PARP1 Gene Silencing. Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2023.02.017
Vancouver
Asai T, Yokota M, Isomura H, Koide H, Sakurai N, Okamoto A, et al. Treatment of PTEN-Null Breast Cancer by a Synthetic Lethal Approach Involving PARP1 Gene Silencing. Journal of Pharmaceutical Sciences. 2023. doi:10.1016/j.xphs.2023.02.017
BibTeX
@article{Asai2023,
author = {Asai, Tomohiro and Yokota, Masafumi and Isomura, Hideki and Koide, Hiroyuki and Sakurai, Naoyuki and Okamoto, Ayaka and Ando, Hidenori and Dewa, Takehisa and Oku, Naoto},
title = {Treatment of PTEN-Null Breast Cancer by a Synthetic Lethal Approach Involving PARP1 Gene Silencing},
journal = {Journal of Pharmaceutical Sciences},
year = {2023},
doi = {10.1016/j.xphs.2023.02.017}
}
EUVIMED